title: [Effects of celecoxib combined with radiotherapy on apoptosis of CNE-2Z cell lines].
abstract: OBJECTIVE
  To investigate the effects of celecoxib combined with radiotherapy on apoptosis of CNE-2Z cell lines and the potential mechanisms.
  
  
  METHODS
  Four groups were used, a control, celecoxib (25 micromol/L celecoxib), irradiation (8 Gy X ray) and celecoxib plus irradiation. The radiosensitising effect was detected by clone formation experiment. Flow cytometry was used to detect the apoptosis rate of cells. The expressions of Bcl-2 and Bax were assessed by immunocytochemistry. Western blot was used to examine the expression of Caspase-3.
  
  
  RESULTS
  Celecoxib enhanced the radiosensitivity of CNE-2Z cells. In experimental group, the mean surviving fraction and the mean lethal dose of CNE-2Z cells were 0.50 and 2.36 respectively. Compared with the irradiated group, there was significant differences between the two groups (P < 0.01). Celecoxib combined with radiotherapy up-regulation the expression of Bax. The score of the expression of Bax in the control group and the experimental group were 1.221 +/- 0.116 and 2.758 +/- 0.256 respectively. Celecoxib combined with radiotherapy could inhibit the expression of the protein of Bcl-2. The score of the expression of Bcl-2 in the control group and the experimental group were 2.559 +/- 0.144 and 1.253 +/- 0.114 respectively, with significant differences (P < 0.01). Celecoxib combined with radiotherapy could increase the apoptosis rate of tumor cells with significant differences (F = 7.63, P < 0.01). Western blot showed that the expression of Caspase-3 was strengthened.
  
  
  CONCLUSIONS
  Celecoxib combined with radiotherapy could induce apoptosis and enhance the radiosensitivity of human nasopharyngeal carcinoma CNE-2Z cell lines.
authors.affiliation: Department of Otorhinolaryngology, First Hospital of Yichang, Yichang 443000, China. xiangyinzhou@sina.com
authors.forename: Yi-zhou
authors.initials: YZ
authors.lastname: Xiang
authors.forename: Lian-zhi
authors.initials: LZ
authors.lastname: Wei
authors.forename: Lin
authors.initials: L
authors.lastname: Yu
authors.forename: Ping
authors.initials: P
authors.lastname: Gui
authors.forename: Ping
authors.initials: P
authors.lastname: Peng
authors.forename: Zhi-jie
authors.initials: ZJ
authors.lastname: Xiong
mesh_terms: D017209:Apoptosis / Q000187:drug effects* / Q000528:radiation effects*; D002277:Carcinoma; D053148:Caspase 3 / Q000378:metabolism; D000068579:Celecoxib; D045744:Cell Line, Tumor / Q000187:drug effects / Q000528:radiation effects; D006801:Humans; D000077274:Nasopharyngeal Carcinoma; D009303:Nasopharyngeal Neoplasms / Q000473:pathology* / Q000628:therapy; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D011720:Pyrazoles / Q000494:pharmacology*; D011878:Radiotherapy; D013449:Sulfonamides / Q000494:pharmacology*; D051028:bcl-2-Associated X Protein / Q000378:metabolism
chemical_list: C494826:BAX protein, human; D019253:Proto-Oncogene Proteins c-bcl-2; D011720:Pyrazoles; D013449:Sulfonamides; D051028:bcl-2-Associated X Protein; C505407:CASP3 protein, human; D053148:Caspase 3; D000068579:Celecoxib